AstraZeneca Plc has resumed the US trial of its experimental Covid-19 vaccine after approval by US regulators, the company said on Friday.
AstraZeneca's US trial was paused on September 6 after a report of a serious neurological illness, believed to be transverse myelitis, in a participant in the company's UK trial.
US Health and Human Services Deputy Chief of Staff Paul Mango also told reporters he was optimistic a US trial by Johnson & Johnson would resume.
J&J paused its large, late-stage trial last week after a study participant became ill and the company said an independent safety panel was investigating.
AstraZeneca trials in